Real-World Healthcare Resource Utilization and Related Costs Associated with Ovarian Cancer in the Brazilian Private Market
Author(s)
Joao Paulo Dos Reis Neto, PhD, MD1, JULIANA BUSCH, MD2;
1Diretor-Presidente da Capesesp, ceo, Rio de Janeiro, Brazil, 2CAPESESP, Rio de Janeiro, Brazil
1Diretor-Presidente da Capesesp, ceo, Rio de Janeiro, Brazil, 2CAPESESP, Rio de Janeiro, Brazil
OBJECTIVES: Ovarian cancer (OC) is the second most common gynecological neoplasm, behind only cervical cancer, and is one of the leading causes of cancer mortality among women in Brazil. Information on the current costs of care for ovarian cancer-across the care continuum is lacking. This study aims to assess the epidemiological data and cost of OC within a Brazilian private market.
METHODS: Retrospective database study using administrative data from January/2019 to December/2023. Adults with malignant neoplasms of the ovarian (ICD-10 C56) were identified. Available data include demographics, comorbidities, healthcare resource utilization (HCRU), and costs, includes visits, surgery, emergency department, therapies and tests. Kaplan-Meier curves were used to estimate the cumulative survival rates. Chi-square and Fisher’s exact and Student’s t tests for categorical/continuous measures were used. Statistical significance for p<0.05.
RESULTS: A total of 33,262 women met the eligibility criteria, 63 patients had OC (65±13 years). 50.0% of all patients were diagnosed and started treatment at late stages (TMN III/IV). First-line treatment involved surgery and/or interval debulking followed by platinum-containing chemotherapy (carboplatin and paclitaxel). Bevacizumab was used in 55% of patients. Annual rates of procedures were: 7.4 for visits, 1.2 for emergency room visits, 72.7 for tests, 5.3 for therapies, and 0.8 for hospitalizations. The average length of hospitalization was 9.4 days. Annualized healthcare costs associated with the OC were U$ 16,501 per patient (51.7% chemotherapy). The cumulative 5-year survival rate was 35.9%.
CONCLUSIONS: Ovarian cancer is associated with delayed diagnosis and poor survival being a significant economic and health burden due to limited treatment efficacy. The costs of treatment are likely to increase as newer, more effective, more expensive treatment regimens become available. The study highlights the importance of developing effective strategies to treat OC and to guide decisions of policymakers regarding the allocation of resources in Brazilian private market.
METHODS: Retrospective database study using administrative data from January/2019 to December/2023. Adults with malignant neoplasms of the ovarian (ICD-10 C56) were identified. Available data include demographics, comorbidities, healthcare resource utilization (HCRU), and costs, includes visits, surgery, emergency department, therapies and tests. Kaplan-Meier curves were used to estimate the cumulative survival rates. Chi-square and Fisher’s exact and Student’s t tests for categorical/continuous measures were used. Statistical significance for p<0.05.
RESULTS: A total of 33,262 women met the eligibility criteria, 63 patients had OC (65±13 years). 50.0% of all patients were diagnosed and started treatment at late stages (TMN III/IV). First-line treatment involved surgery and/or interval debulking followed by platinum-containing chemotherapy (carboplatin and paclitaxel). Bevacizumab was used in 55% of patients. Annual rates of procedures were: 7.4 for visits, 1.2 for emergency room visits, 72.7 for tests, 5.3 for therapies, and 0.8 for hospitalizations. The average length of hospitalization was 9.4 days. Annualized healthcare costs associated with the OC were U$ 16,501 per patient (51.7% chemotherapy). The cumulative 5-year survival rate was 35.9%.
CONCLUSIONS: Ovarian cancer is associated with delayed diagnosis and poor survival being a significant economic and health burden due to limited treatment efficacy. The costs of treatment are likely to increase as newer, more effective, more expensive treatment regimens become available. The study highlights the importance of developing effective strategies to treat OC and to guide decisions of policymakers regarding the allocation of resources in Brazilian private market.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD50
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Oncology